Latest News-Everest Medicine Mediaroom_Page

Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference

SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"...

2026-01-06 07:58 13002

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-17 16:10 4317

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

SHANGHAI, Dec. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-12-15 12:40 4397

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

- Accretive Commercialization Services Agreement covering six mature assets across critical care, c...

2025-12-11 23:57 4730

Everest Medicines Announces First Patient Dosed in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

* The first patient had received the first dose of EVM14 injection in a global, multi-center Phas...

2025-11-21 12:01 3316

Everest Medicines Acquires Exclusive Greater China and Other Asian Country Rights to VIS-101, a Novel Bifunctional Biologic for Serious Eye Disorders

* Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-...

2025-10-30 11:05 2766

Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14

SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-10-14 12:13 2287

Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14

* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receiv...

2025-10-13 08:47 2171

Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized...

2025-10-09 13:10 2109

Real-World Evidence of NEFECON® to Be Presented in Seven New Abstracts at the 18th International lgAN Symposium

* 7 new NEFECON® real-world evidence abstracts will be presented at the 18th International lgA Ne...

2025-09-15 07:45 5854

Everest Medicines Announces Interim Results for First Half of 2025

SHANGHAI, Aug. 29, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-08-29 07:52 4687

Everest Medicines Announces Participation in September Investor Conferences

SHANGHAI, Aug. 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-08-25 20:57 2410

Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC

Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Compan...

2025-08-15 09:35 2810

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company...

2025-08-14 12:02 3069

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

* As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of E...

2025-07-02 15:33 2812

Latest News